Filing Analysis
Health In Tech, Inc. filed an 8-K to announce the hosting of a conference call on August 13, 2026, regarding its financial and operating results for the quarter ended June 30, 2026.
📋 Key Facts
- Conference call held on August 13, 2026, to discuss Q2 2026 results (quarter ended June 30, 2026).
- A transcript of the earnings call is provided as Exhibit 99.1.
- The company is an emerging growth company.
- Replay of the call available for 90 days via the Investor Relations website.
Health In Tech, Inc. issued an 8-K to announce its quarterly results of operations for the period ending June 30, 2026.
📋 Key Facts
- Report date: August 13, 2026
- Reporting period: Quarter ended June 30, 2026
- The company is an emerging growth company
- Results were released via press release (Exhibit 99.1)
Health In Tech, Inc. has filed an 8-K to furnish an investor presentation intended for use at upcoming conferences and meetings.
📋 Key Facts
- The filing is pursuant to Item 7.01 (Regulation FD Disclosure).
- An investor presentation was prepared by the Company on August 13, 2026.
- The presentation is furnished as Exhibit 99.1 and is not considered 'filed' for purposes of Section 18 liability.
Health In Tech, Inc. furnished a transcript of its earnings conference call held on May 13, 2026, regarding financial and operating results for the quarter ended March 31, 2026.
📋 Key Facts
- Earnings call held on May 13, 2026
- Covers fiscal quarter ended March 31, 2026
- Transcript provided as Exhibit 99.1
- Replay available on investor relations website for 90 days
Health In Tech, Inc. furnished an investor presentation on May 13, 2026, intended for use at upcoming conferences and meetings. This filing is a standard Regulation FD disclosure and does not report any material changes to the company's financial condition or operations.
📋 Key Facts
- The filing was made on May 13, 2026, under Item 7.01 (Regulation FD Disclosure).
- The company prepared an investor presentation (Exhibit 99.1) for use in meetings with officers and representatives.
- The information is 'furnished' and not 'filed' for purposes of Section 18 of the Exchange Act.
- The report was signed by Tim Johnson, Chief Executive Officer.
Health In Tech, Inc. announced its financial results for the first quarter ended March 31, 2026, via a press release on May 13, 2026. The filing serves as a standard disclosure of quarterly operations and financial condition.
📋 Key Facts
- The report covers the fiscal quarter ended March 31, 2026.
- The press release was issued and filed on May 13, 2026.
- The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
- Tim Johnson, Chief Executive Officer, signed the report.
Dustin Plantholt departed from his role as Chief AI & Marketing Officer of Health In Tech, Inc. effective April 30, 2026. He has transitioned into a consulting role through a subsidiary, HITChain Inc., where he will receive monthly fees and a significant equity grant.
🚩 Red Flags
- Departure of a C-suite officer (Chief AI & Marketing Officer).
- Transition of a former officer to a consultant role, which can sometimes indicate a negotiated exit strategy.
- Issuance of 500,000 shares in a subsidiary (HITChain Inc.) rather than the parent company, which may complicate the corporate structure.
📋 Key Facts
- Dustin Plantholt departed as Chief AI & Marketing Officer effective April 30, 2026.
- The departure is described as part of a 'business transition' and not a disagreement with the company.
- Plantholt entered into a Consulting Agreement via Plantholt Advisory Group LLC with subsidiary HITChain Inc. starting May 1, 2026.
- The consultant will receive monthly compensation and 500,000 restricted shares of HITChain Inc. common stock.
- The Restricted Stock Award vests in equal monthly installments over 12 months.
- The Consulting Agreement can be terminated by either party upon 10 days' prior written notice.
Health In Tech, Inc. furnished an investor presentation on March 25, 2026, intended for use at upcoming conferences and meetings. The filing serves as a standard Regulation FD disclosure to ensure public access to information shared with investors.
📋 Key Facts
- The company prepared an investor presentation for use at conferences and meetings starting March 25, 2026.
- The presentation is furnished as Exhibit 99.1.
- The filing was made under Item 7.01 (Regulation FD Disclosure).
- Health In Tech, Inc. is classified as an emerging growth company.
- The company's Class A Common Stock is traded on the Nasdaq Capital Market under the symbol HIT.
Health In Tech, Inc. announced the closing of its previously disclosed private investment in public equity (PIPE) financing on March 27, 2026. The company issued a press release to confirm the completion of the capital raise, though specific dollar amounts and share counts were not detailed in the main body of the 8-K.
🚩 Red Flags
- PIPE financings in micro-cap companies are typically dilutive to existing Class A Common Stock holders.
- The 8-K lacks specific financial terms (valuation, share price, or total proceeds) within the narrative, relying on an exhibit.
📋 Key Facts
- The company closed a PIPE financing on March 27, 2026.
- The transaction was previously announced and has now reached finality.
- Health In Tech, Inc. is listed on the Nasdaq Capital Market under the ticker HIT.
- The filing was signed by CEO Tim Johnson.
Health In Tech, Inc. entered into a securities purchase agreement for a $7.0 million PIPE financing involving the issuance of 5,600,000 shares of common stock to accredited investors. The company intends to use the proceeds for sales expansion, technology development, and working capital.
🚩 Red Flags
- Significant dilution of existing shareholders through the issuance of 5.6 million new shares.
- The use of a PIPE (Private Investment in Public Equity) often suggests a need for rapid capital that may not be available through traditional public offerings.
📋 Key Facts
- The company is issuing 5,600,000 shares of Class A Common Stock.
- Gross proceeds are expected to be approximately $7.0 million before fees.
- The transaction is a Private Investment in Public Equity (PIPE) scheduled to close around March 27, 2026.
- Craig-Hallum Capital Group LLC served as the sole placement agent.
- The company must file a resale registration statement within 30 calendar days of the agreement.
- Directors and officers are subject to a 60-day lock-up period following the effectiveness of the registration statement.
Health In Tech, Inc. issued a press release on March 25, 2026, announcing its financial results for the fourth quarter and full fiscal year ended December 31, 2025.
📋 Key Facts
- The filing reports financial results for the period ended December 31, 2025.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
- The company is an emerging growth company listed on the Nasdaq Capital Market under the ticker 'HIT'.
- Tim Johnson is identified as the Chief Executive Officer.
Health In Tech, Inc. announced that its executive management team, vice presidents, and Board of Directors have voluntarily entered into lock-up agreements. These agreements extend the original twelve-month post-IPO lock-up period by an additional six months.
🚩 Red Flags
- Extension of lock-up periods can sometimes indicate management's desire to avoid immediate downward pressure from insider selling, though here it is characterized as voluntary.
📋 Key Facts
- Lock-Up Holders include executive management, VPs, and the Board of Directors.
- The voluntary extension moves the expiration date of the lock-up to June 20, 2026.
- The original twelve-month lock-up period was established in connection with the IPO filed on December 20, 2024.
- The agreement prohibits holders from selling or transferring Class A Common Stock during this extended period.
Health In Tech, Inc. announced the termination of its Chief Technology Officer, Imran Yousuf, effective November 25, 2025.
📋 Key Facts
- Imran Yousuf was terminated from his position as Chief Technology Officer on November 25, 2025.
- The termination was 'without cause'.
- The company explicitly stated the departure was not due to any disagreement regarding operations, policies, or practices.
Health In Tech, Inc. filed an 8-K to announce the hosting of a conference call on November 10, 2025, regarding its financial and operating results for the quarter ended September 30, 2025.
📋 Key Facts
- Conference call held on November 10, 2025, to discuss Q3 2025 results.
- Transcript of the earnings call is provided as Exhibit 99.1.
- A replay of the conference call will be available until approximately February 8, 2026.
Health In Tech, Inc. filed an 8-K to announce its quarterly results of operations for the period ended September 30, 2025 via a press release.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Results of Operations).
- Reporting period: Quarter ended September 30, 2025.
- Date of report/event: November 10, 2025.
- Company status: Emerging growth company.
Health In Tech, Inc. has furnished an investor presentation intended for use at upcoming conferences and meetings. This filing is a routine disclosure under Item 7.01 to provide supplemental information to the market.
📋 Key Facts
- The company prepared an investor presentation on November 10, 2025.
- The presentation is intended for use by officers and representatives at conferences and meetings.
- Information provided under Item 7.01 is 'furnished' rather than 'filed', meaning it is not subject to the liabilities of Section 18 of the Exchange Act.
Health In Tech, Inc. held its 2025 Annual Meeting of Stockholders on October 3, 2025, where stockholders approved the election of five directors and an amendment to the 2024 Equity Incentive Plan. Additionally, MaloneBailey, LLP was ratified as the company's independent auditors for fiscal year 2025.
🚩 Red Flags
- Increase in authorized share count (Equity Incentive Plan amendment) can lead to future dilution of existing shareholders.
📋 Key Facts
- Annual Meeting held on October 3, 2025, with a quorum representing 99.33% of outstanding voting power (161,619,722 votes).
- All five nominees for the Board of Directors were re-elected to serve until the 2026 annual meeting.
- Stockholders approved an amendment to the 2024 Equity Incentive Plan to increase authorized Class A shares from 7,677,849 to 10,677,849 and allow for up to 2,000,000 Class B shares/options for executive officers.
- MaloneBailey, LLP was ratified as independent auditors for the fiscal year ending December 31, 2025.
Health In Tech, Inc. announced the grant of restricted stock awards (RSAs) to its CEO and CFO on September 24, 2025. These grants are tied to the development and successful launch of a new corporate initiative.
🚩 Red Flags
- Related-party compensation: Significant equity grants to top executives tied to speculative future milestones (LOI/MOU and beta launch) rather than traditional time-based vesting.
- Potential dilution: Total of 160,000 new shares issued via RSAs.
📋 Key Facts
- CEO Tim Johnson granted 80,000 shares of restricted stock.
- CFO Linlin (Julia) Qian granted 80,000 shares of restricted stock.
- Vesting is split into three tranches: signing a LOI/MOU, entering proof-of-concept/beta launch, and full commercial launch of the 'Initiative'.
- Each tranche vests in equal monthly installments over a 12-month period.
Health In Tech, Inc. announced the grant of restricted stock awards (RSAs) to its CEO, CFO, and CTO in connection with the development of two new programs ('Program 1' and 'Program 2'). The vesting of these shares is contingent upon the successful launch and operational status of these specific programs.
🚩 Red Flags
- Performance-based vesting tied to 'successful launch' is subjective and creates potential misalignment if definitions of 'operational' are loosely defined.
- Significant equity dilution for management linked to specific internal projects (Program 1 & 2) rather than general company performance.
📋 Key Facts
- CEO Tim Johnson granted 34,000 total RSAs (17,000 for Program 1; 17,000 for Program 2).
- CFO Linlin (Julia) Qian granted 27,000 total RSAs (10,000 for Program 1; 17,000 for Program 2).
- CTO (Mo) Imran Yousuf granted 7,000 total RSAs (3,500 for Program 1; 3,500 for Program 2).
- Vesting is split: 50% vests over 12 months upon successful launch of Program 1; 50% vests over 12 months upon successful launch of Program 2.
- Grants were approved by the Compensation Committee on August 15, 2025.
Health In Tech, Inc. announced the termination of Chief Operating Officer Chris Kurtenbach's at-will employment on July 22, 2025.
📋 Key Facts
- Effective date of departure: July 22, 2025
- Individual terminated: Chris Kurtenbach
- Position: Chief Operating Officer (COO)
- Nature of termination: At-will employment
Health In Tech, Inc. has furnished an investor presentation intended for use at upcoming conferences and meetings. This is a routine disclosure under Item 7.01 to provide non-binding information to the market.
📋 Key Facts
- The company prepared an investor presentation on July 21, 2025.
- The presentation is intended for use at conferences and meetings by officers and representatives.
- Information provided under Item 7.01 is 'furnished' rather than 'filed', meaning it is not subject to the liabilities of Section 18 of the Exchange Act.
Health In Tech, Inc. has filed an 8-K to announce its quarterly results of operations for the period ending June 30, 2025.
📋 Key Facts
- The filing was made on July 21, 2025.
- The company is reporting results for the quarter ended June 30, 2025.
- The report includes a press release as Exhibit 99.1 regarding operational results.
Health In Tech, Inc. received a notice from Nasdaq indicating the company is in violation of the minimum $1.00 bid price requirement for continued listing on the Nasdaq Capital Market. The company has been granted an initial 180-day period to regain compliance by October 27, 2025.
🚩 Red Flags
- Delisting notice from Nasdaq
- Potential requirement for a reverse stock split to regain compliance
- Prolonged period of sub-$1.00 trading (30+ consecutive business days)
📋 Key Facts
- Received Nasdaq Staff Letter on April 28, 2025.
- Violation of Nasdaq Listing Rule 5550(a)(2) due to closing bid price being below $1.00 for 30 consecutive business days.
- Initial compliance period expires October 27, 2025.
- To regain compliance, the stock must close at $1.00 or more for at least 10 consecutive business days before the deadline.
- The company may be eligible for a second 180-day compliance period if it meets other market value requirements and intends to cure the deficiency via methods such as a reverse stock split.
Health In Tech, Inc. announced the resignation of Board member Lynn Liang and a reduction in the size of the Board of Directors.
🚩 Red Flags
- Reduction in Board size (from 7 to 6) can sometimes indicate internal restructuring or shifting governance dynamics, though not explicitly stated here.
📋 Key Facts
- Lynn Liang is resigning from the Board effective April 18, 2025.
- Ms. Liang previously served on the Compensation Committee.
- The resignation is attributed to professional and personal commitments and not a disagreement with the Company or Board.
- The Board of Directors will be reduced from seven members to six members, effective April 18, 2025.
Health In Tech, Inc. has furnished an investor presentation intended for use at upcoming conferences and meetings. This is a standard regulatory disclosure under Item 7.01 to provide transparency regarding non-public information being shared with investors.
📋 Key Facts
- The company prepared an investor presentation on April 14, 2025.
- The presentation is intended for use at conferences and meetings by officers and representatives.
- Information provided under Item 7.01 is 'furnished' rather than 'filed', meaning it is not subject to the liabilities of Section 18 of the Exchange Act.
Health In Tech, Inc. filed an 8-K to announce its quarterly results of operations for the period ending March 31, 2025.
📋 Key Facts
- The filing was made on April 14, 2025.
- The company is reporting results for the quarter ended March 31, 2025.
- The report includes a press release as Exhibit 99.1 regarding operational results.
Health In Tech, Inc. announced the expansion of its Board of Directors from six to seven members with the election of Sanjay Shrestha. Mr. Shrestha will serve on the Audit, Nominating and Corporate Governance, and Compensation Committees.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Board size increased from 6 to 7 directors effective April 8, 2025.
- Sanjay Shrestha elected to the Board for a one-year term.
- Mr. Shrestha appointed to Audit Committee, Nominating and Corporate Governance Committee, and Compensation Committee.
- Company intends to enter into an indemnification agreement with Mr. Shrestha.
Health In Tech, Inc. filed an 8-K to furnish an investor presentation intended for use at upcoming conferences and meetings.
📋 Key Facts
- The company prepared an investor presentation on March 17, 2025.
- The presentation is being furnished under Item 7.01 (Regulation FD Disclosure).
- Information in the presentation is 'furnished' rather than 'filed', meaning it is not subject to Section 18 liability or incorporation by reference.
Health In Tech, Inc. filed an 8-K to announce its results of operations for the quarter and fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: March 17, 2025
- Reporting period covered: Quarter and Year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) regarding financial results.
- Company is an emerging growth company.
Health In Tech, Inc. has adopted its Third Amended and Restated Bylaws effective February 25, 2025. The primary changes involve expanding the Board of Directors from seven to eleven members and restructuring director terms.
📋 Key Facts
- Board size increased from 7 directors to 11 directors.
- Director terms restructured: first two directors have initial three-year terms with one-year reelections; all other directors serve one-year terms.
- The Third Amended and Restated Bylaws became effective on February 25, 2025.
Health In Tech, Inc. (HIT) successfully completed an initial public offering of 2,300,000 shares at $4.00 per share, resulting in approximately $7.27 million in net proceeds. The company intends to use the funds for system enhancements, business expansion, and working capital.
🚩 Red Flags
- Use of proceeds includes 'working capital and other general corporate purposes,' which can sometimes mask liquidity issues, though common in IPOs.
📋 Key Facts
- Completed offering of 2,300,000 shares of Class A Common Stock at $4.00 per share.
- Underwriters included American Trust Investment Services, Inc. as the representative.
- Net proceeds from the offering totaled approximately $7.27 million after expenses and commissions.
- The SEC declared the Registration Statement effective on December 19, 2024.
- Company granted underwriters a 30-day option to purchase up to 345,000 additional shares for over-allotments.